[REG-07] National Health Programmes of India (NTEP, NVBDCP, NACO, NHM, PMBJP Jan Aushadhi) & Pharmacist Role
REG-07 • 11. Community PharmacyLearning Objectives
Synthesize diagnostic and treatment regimens across India's flagship National Health Programmes (NTEP for TB, NVBDCP for Malaria/Dengue/Filariasis/Kala-Azar, NACO for HIV/AIDS, NLEP for Leprosy, NPCBVI, NPCDCS).; Explain the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP — PMBI, WHO-GMP NABL-tested generic medicines at 50–90% lower cost) and Ayushman Bharat (PM-JAY).; Apply NLEP Multidrug Therapy (MDT: [8.53] Rifampicin + [8.56] Dapsone + Clofazimine) and Mass Drug Administration (MDA) for Lymphatic Filariasis ([8.83] DEC + [8.81] Albendazole + [8.84] Ivermectin).
Chapter Overview & Core Explanation
India's National Health Programmes deliver free, standardized, evidence-based drug regimens from tertiary medical colleges down to rural Primary Health Centres (PHCs) and Jan Aushadhi Kendras to eliminate tuberculosis, malaria, leprosy, filariasis, and maternal-child mortality.
Key Exam & Clinical Takeaways
- Under NCVBDC guidelines, single-dose Liposomal Amphotericin B ([8.72], 10 mg/kg IV) is the first-line treatment of choice for Visceral Leishmaniasis (Kala-Azar) in India.
- Under NTEP, all TB patients registered on the Ni-kshay portal receive direct benefit transfer (DBT) nutritional support under the Nikshay Poshan Yojana.